Caplin Point Laboratories Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Caplin Point Laboratories Ltd is ₹ 1710 as of 30 Apr 15:30 . The P/E Ratio of Caplin Point Laboratories Ltd changed from 12.6 on March 2021 to 28.4 on March 2025 . This represents a CAGR of 17.65% over 5 yearsThe P/E Ratio of Shukra Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Caplin Point Laboratories Ltd changed from ₹ 3057 crore on March 2021 to ₹ 15222 crore on March 2025 . This represents a CAGR of 37.86% over 5 yearsThe Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Caplin Point Laboratories Ltd for the Dec '25 is ₹ 576.45 crore as compare to the Sep '25 revenue of ₹ 564.43 crore. This represent the growth of 2.13% The revenue of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 39.95 crore as compare to the Sep '25 revenue of ₹ 7.59 crore. This represent the growth of 426.35% The ebitda of Caplin Point Laboratories Ltd for the Dec '25 is ₹ 223.35 crore as compare to the Sep '25 ebitda of ₹ 219.56 crore. This represent the growth of 1.73% The ebitda of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 27.95 crore as compare to the Sep '25 ebitda of ₹ 1.29 crore. This represent the growth of 2066% The net profit of Caplin Point Laboratories Ltd changed from ₹ 140.07 crore to ₹ 165.86 crore over 7 quarters. This represents a CAGR of 10.14% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ 20.36 crore over 7 quarters. This represents a CAGR of 189.96% The Dividend Payout of Caplin Point Laboratories Ltd changed from 14.53 % on March 2021 to 13.43 % on March 2025 . This represents a CAGR of -1.56% over 5 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Caplin Point Laboratories Ltd

Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16, 1990.
The Company is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market.
Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India.
It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections. Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries.
In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Caplin Point Laboratories Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Caplin Point Laboratories Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Caplin Point Laboratories Ltd is 13,002 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,272 Cr

What are the key factors driving the stock performance of Caplin Point Laboratories Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Caplin Point Laboratories Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Caplin Point Laboratories Ltd and Shukra Pharmaceuticals Ltd?

As of May 3, 2026, the Caplin Point Laboratories Ltd stock price is INR ₹1710.6. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹29.07.

How do dividend payouts of Caplin Point Laboratories Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Caplin Point Laboratories Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.